Business Context and Reporting Period
This Form 10-Q covers LecTec Corporation (not Axogen, Inc.) for the quarterly period ended September 30, 1998. The company manufactures conductive products, medical tapes, and therapeutic products. The report is unaudited and reflects the first quarter of fiscal 1999.
Key Financial Metrics
| Metric | Q1 1999 (Sep 30) | Q1 1998 (Sep 30) |
|---|---|---|
| Net Sales | $2,903,057 | $3,630,810 |
| Gross Profit | $1,017,253 | $1,208,859 |
| Gross Margin | 35.0% | 33.3% |
| Operating Loss | $(182,754) | $170,576 (Income) |
| Net Loss | $(152,217) | $151,693 (Income) |
| Cash from Operations | $208,504 | $(102,023) |
| Cash and Equivalents | $2,005,757 | $579,695 |
| Working Capital | $5,021,366 | $5,335,861 |
| Debt | $0 | $0 |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 20.0% year-over-year. This was driven by a 66.0% drop in therapeutic products (loss of CNS, Inc. and a direct marketing distributor), a 28.0% drop in medical tapes (absence of a large intermittent customer), and a 3.6% drop in conductive products.
- Profitability Shift: The company swung from a net income of $151,693 in Q1 1998 to a net loss of $152,217 in Q1 1999. Despite lower sales, gross margin improved to 35.0% due to lower obsolescence and labor costs.
- Expense Increases: Operating expenses rose significantly. Sales and marketing increased 28.1% (to $333,533) due to staffing and travel for the new TheraPatch launch. General and administrative expenses rose 10.4% (to $586,461) due to added regulatory and quality assurance staff.
- Cash Flow: Operating cash flow turned positive ($208,504) compared to a negative $102,023 in the prior year, despite the net loss, largely due to changes in working capital (specifically accounts payable).
Outlook, Risks, and Management Commentary
- New Product Launch: The company launched the TheraPatch family of analgesic patches in September 1998. Management anticipates sales and marketing expenses as a percentage of sales will remain elevated for the remainder of fiscal 1999 due to this launch.
- Stock Repurchase: The company repurchased 90,850 shares for $300,675 during the quarter. As of November 11, 1998, total repurchases under the program reached 156,750 shares for $538,813.
- Liquidity: The company has no debt. A $1,000,000 working capital line of credit expired in September 1998 with no borrowings outstanding. Management expects existing cash and the renewal of the line of credit to be sufficient for operations.
- Year 2000 (Y2K) Risk: The company is approximately 75% complete with internal and third-party Y2K compliance programs. While core systems are compliant, risks remain regarding third-party service providers (electricity, water, telephone). Costs incurred to date are immaterial.
- Forward-Looking Risks: Risks include dependence on major customers, competitive pricing pressures, regulatory approvals, and potential Y2K disruptions.
Investor Verification Checklist
- Verify the sustainability of the new TheraPatch product line and whether it can offset the loss of the CNS, Inc. therapeutic product revenue.
- Confirm the renewal status and terms of the $1,000,000 working capital line of credit that expired in September 1998.
- Monitor the progress of Y2K compliance for critical third-party vendors and service providers.
- Assess the impact of continued elevated sales and marketing expenses on future profitability.
- Review the inventory buildup ($128,554 increase) related to the TheraPatch launch to ensure it aligns with sales forecasts.